<table>
<thead>
<tr>
<th>Cancer category</th>
<th>Trial title</th>
<th>Trial description</th>
<th>Principal Investigator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Haematology - MPN</td>
<td>PERSIST</td>
<td>A randomised Phase III trial comparing pacritinib (a novel JAK2/FLT3 inhibitor) with best available therapy in patients with myelofibrosis.</td>
<td>Green, Prof Tony</td>
</tr>
<tr>
<td>Haematology - MPN</td>
<td>MAJIC</td>
<td>A randomised Phase III trial comparing Ruxolitinib (a JAK2 inhibitor) in patients with high risk essential thrombocytopenia or high risk polycythaemia vera who are resistant or refractory to Hydroxycarbamide.</td>
<td>Green, Prof Tony</td>
</tr>
<tr>
<td>Haematology - MPN</td>
<td>PEGASYS</td>
<td>A randomised Phase III trial comparing pegylated-interferon alfa2a (PEGASYS) with hydroxycarbamide in newly diagnosed patients with high risk essential thrombocytopenia or high risk polycythaemia vera</td>
<td>Green, Prof Tony</td>
</tr>
<tr>
<td>Haematology - MPN</td>
<td>The Causes of Clonal Blood Cell Disorders</td>
<td>The Causes of Clonal Blood Cell Disorders</td>
<td>Green, Prof Tony</td>
</tr>
<tr>
<td>Haematology - MPN</td>
<td>CHOP-OR: Study of CHOP with Ofatumumab in patients with Richter’s Syndrome</td>
<td>Single arm NCRI feasibility study of CHOP in combination with Ofatumumab in induction and maintenance for patients with newly diagnosed Richter’s Syndrome</td>
<td>Follows, Dr George</td>
</tr>
<tr>
<td>Haematology</td>
<td>CMV-IMPACT</td>
<td>A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in combination with Conventional Antiviral Drug Therapy for the treatment of CMV Reactivation Episodes in Patients following Allogeneic Haematopoietic Stem Cell Transplant</td>
<td>Crawley, Dr Charles</td>
</tr>
<tr>
<td>Haematology</td>
<td>CONTINUUM</td>
<td>A Phase 3 Multicentre, randomised, double-blind, placebo-controlled. Parallel-group study of the efficacy and safety of Lenalidomide (Revlimid®) as maintenance therapy for patients with B-cell chronic lymphocytic leukaemia following second line therapy</td>
<td>Follows, Dr George</td>
</tr>
<tr>
<td>Haematology</td>
<td>FACT study Gallium</td>
<td>Factors associated with Childhood Tumours Study</td>
<td>Follows, Dr George</td>
</tr>
<tr>
<td>Haematology</td>
<td>GILEAD 0117 Phase 3 Extension Study of GS-1101 in CLL - Protocol ID: GS-US-312-0117</td>
<td>This clinical trial (Study GS-US-312-0117) is a separate, multicentre, 2-arm, double-blind, parallel-group extension study that is a companion trial to Study GS-US-312-0116; in this trial, compliant subjects from GS-US-312-0116 who are tolerating primary study therapy but experience definitive CLL progression are eligible to receive active blinded GS-1101 therapy at the standard dose or a higher dose, with allocation based on the original primary study randomisation. Treatment Groups: • Arm A: GS-1101 + rituximab (Study GS-US-312-0116) ⇒ high-dose GS-1101 (300 mg BID) (Study GS-US-312-0117) • Arm B: Placebo + rituximab (Study GS-US-312-0116) ⇒ standard-dose GS-1101 (150 mg BID) (Study GS-US-312-0117) Treatment Assignment: • Assignment to Arm A or Arm B with allocation based on the original primary study randomization • Implementation through an interactive web response system (IWRS)</td>
<td>Follows, George</td>
</tr>
</tbody>
</table>
Haematology LenaRIC Phase II study of the adjuvant use of lenalidomide in patients undergoing reduced intensity conditioning allogenic transplantation for multiple myeloma

Haematology MAC UCBT Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a myeloablative conditioning regimen

Haematology MDS 005 A multicentre, randomized, double-blind, placebo-controlled, 3-arm study of the efficacy and safety of 2 doses of Lenalidomide versus placebo in red blood cell (RBC) transfusion-dependent subjects with low-or intermediate-1-risk myelodysplastic syndromes

Haematology MDS REGISTRY A prospective, multicenter European Registry for newly diagnosed patients with Myelodysplastic Syndromes of IPSS low and intermediate-1 subtypes.

Haematology MiniAllo Phase II study of low intensity allogeneic transplantation in Mantle Cell Lymphoma

Haematology MLN9708 in combination with Melphalan and and Prednisolone An Open-Label, Dose-Escalation, Phase 1/2 Study of the Oral Form of MLN9708, a Next-Generation Proteasome Inhibitor, Administered in Combination With a Standard Care Regimen of Melphalan and Prednisone in Patients With Newly Diagnosed Multiple Myeloma Requiring Systemic Treatment

Haematology MO25455 A Study Comparing Maintenance Subcutaneous MabThera/Rituxan (Rrituximab) With Observation Only in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma Who Had Responded to MabThera-Based Immunochemotherapy Induction and Two Years of Maintenance With Subcutaneous MabThera.

Haematology MRC CLL5 The value of autografting younger patients with high risk chronic lymphocytic leukaemia (cll). A randomised phase III intergroup trial

Haematology NCRN264 VALOR - Safety study of Vosaroxin + Cytarabine vs placebo + Cytarabine in AML A Phase 3, Randomized, Controlled, Double-Blind, Multinational Clinical Study of the Efficacy and Safety of Vosaroxin and Cytarabine Versus Placebo and Cytarabine in Patients With First Relapsed or Refractory Acute Myeloid Leukemia

Haematology NCRN316 - Rixutimab in non-Hodgkin’s lymphoma A randomized study comparing maintenance therapy with subcutaneous rituximab continued until progression with observation only in patients with relapsed or refractory, indolent non-Hodgkin’s lymphoma who completed and responded to rituximab-based immunochemotherapy induction and initial 2-year rituximab maintenance therapy administered subcutaneously.

Haematology NCRN375: CAL-101 + Rituximab for Previously Treated CLL A Phase 3, Randomized, Double-Blind, Placebo Controlled Study Evaluating the Efficacy and Safety of GS 1101 (CAL-101) in Combination with Rituximab for Previously Treated Chronic Lymphocytic Leukemia


Haematology NHL_MRS Magnetic Resonance Spectroscopy Study of Non-Hodgkin’s Lymphoma


Haematology PACIFICO Alkylator Combination In Follicular Lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC (previous acronym: RICH FLO)

Haematology PADIMAC Phase II study of Bortezomib, Adriamycin and Dexamethasone (PAD) therapy for previously untreated patients with multiple myeloma: Impact of minimal residual disease (MRD) in patients with deferred ASCT (PADIMAC)

Haematology PAIRed PAIReD (Pilot of Allogeneic Immunotherapy in Refractory Disease): Phase II study of reduced intensity allogeneic transplantation for refractory Hodgkin lymphoma
Haematology PICLLe Phase I/II clinical trial to assess the efficacy and safety of olaparib, a PARP-inhibitor, in relapsed and refractory Chronic Lymphocytic Leukaemia patients with an 11q deletion or ATM mutation and relapsed/refractory patients with T-Prolymphocytic Leukaemia and Mantle Cell Lymphoma.

Haematology PROmPT Platelet Responsiveness and Outcome from Platelet Transfusion PROmPT: Platelet Responsiveness and Outcome from Platelet Transfusion Does inherent variation in donor platelet function affect the clinical efficacy of apheresis platelets? A randomised double blind single centre trial

Haematology ProT4 (Prophylactic Transfer of CD4 Lymphocytes) Multicentre randomised phase II study to evaluate the efficacy of prophylactic transfer of CD4 lymphocytes after T-cell depleted reduced intensity HLA-identical sibling transplantation for indolent non-Hodgkin's lymphoma and CLL

Haematology ReACH ReACH (Reduced Intensity Allografting for Chemosensitive Hodgkin Lymphoma): Phase II study of reduced intensity sibling allogeneic transplantation for relapsed, chemo-sensitive, PET positive Hodgkin lymphoma

Haematology RIC UCBT Transplantation of umbilical cord blood from unrelated donors in patients with haematological diseases using a reduced intensity conditioning regimen

Haematology Roche (GOYA) A Phase III, Multicenter, Open-label Randomized Trial Comparing the Efficacy of GA101 [RO5072759] in Combination With CHOP (G-CHOP) Versus Rituximab and CHOP (R-CHOP) in Previously Untreated Patients With CD20-positive Diffuse Large B-cell Lymphoma (DLBCL)

Haematology UKALL 14 A randomized trial for adults with newly diagnosed acute lymphoblastic leukaemia

Follows, Dr George

Foukanelli, Dr Theodora

Crawley, Dr Charles

Crawley, Dr Charles

Crawley, Dr Charles

Follows, Dr George

Craig, Dr Jenny